Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.

Case series

“We present our experience using Tirzepatide in two adolescent patients with obesity and MASLD.”

Two 18-year-old adolescents with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)

“we present a case series of two 18‐year‐old adolescents with obesity and MASLD treated with Tirzepatide.”

2

“We present our experience using Tirzepatide in two adolescent patients with obesity and MASLD.”

13 to 15 months for Case 1 and 3 months for Case 2

“Thirteen months after initiation of Tirzepatide in conjunction with lifestyle modification, repeat MRE noted improvement of steatosis with PDFF decrease to 12% (absolute change of −19.5%) and continued normal stiffness (Figure 1).”

Improvement in anthropometric, biochemical, and radiological outcomes including weight, BMI, liver enzymes, and steatosis markers

“Patients treated with Tirzepatide had improvement in anthropometric, biochemical, and radiological outcomes in MASLD.”

Tirzepatide was well tolerated with no significant adverse events reported in the cases

“Both cases demonstrate utilization of Tirzepatide in adolescent patients with good tolerability and favorable response.”

Reductions in ALT and GGT exceeded thresholds associated with histological improvement in prior studies

“Reductions in ALT and GGT exceeded 40% and 20%, respectively, which are thresholds that have been associated with histological improvement in steatohepatitis in prior studies.”

Absence of liver biopsy, small sample size, and limited follow-up duration

“Most notably, the absence of liver biopsy precludes diagnosis of definitive diagnosis of MASH, fibrosis staging, and confirmation of histologic response.”